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ABSTRACT Antibacterial activity screening of a collection of Xenorhabdus strains led
to the discovery of the odilorhabdins, a new antibiotic class with broad-spectrum ac-
tivity against Gram-positive and Gram-negative pathogens. Odilorhabdins inhibit
bacterial translation by a new mechanism of action on ribosomes. A lead optimiza-
tion program identiﬁed NOSO-502 as a promising candidate. NOSO-502 has MIC val-
ues ranging from 0.5 to 4 g/ml against standard Enterobacteriaceae strains and
carbapenem-resistant Enterobacteriaceae (CRE) isolates that produce KPC, AmpC, or
OXA enzymes and metallo--lactamases. In addition, this compound overcomes mul-
tiple chromosome-encoded or plasmid-mediated resistance mechanisms of acquired
resistance to colistin. It is effective in mouse systemic infection models against Esch-
erichia coli EN122 (extended-spectrum -lactamase [ESBL]) or E. coli ATCC BAA-2469
(NDM-1), achieving a 50% effective dose (ED50) of 3.5 mg/kg of body weight and 1-,
2-, and 3-log reductions in blood burden at 2.6, 3.8, and 5.9 mg/kg, respectively, in
the ﬁrst model and 100% survival in the second, starting with a dose as low as 4
mg/kg. In a urinary tract infection (UTI) model with E. coli UTI89, urine, bladder, and
kidney burdens were reduced by 2.39, 1.96, and 1.36 log10 CFU/ml, respectively, af-
ter injection of 24 mg/kg. There was no cytotoxicity against HepG2, HK-2, or human
renal proximal tubular epithelial cells (HRPTEpiC), no inhibition of hERG-CHO or Nav
1.5-HEK current, and no increase of micronuclei at 512 M. NOSO-502, a compound
with a new mechanism of action, is active against Enterobacteriaceae, including all
classes of CRE, has a low potential for resistance development, shows efﬁcacy in sev-
eral mouse models, and has a favorable in vitro safety proﬁle.
KEYWORDS inhibitor, bacterial translation, carbapenem-resistant Enterobacteriaceae,
preclinical candidate
Antibiotic-resistant infections are spreading around the world. The urgent needto discover new families of antibacterial agents to counter the threat of
drug-resistant infection is widely recognized. The U.S. Centers for Disease Control
and Prevention (CDC) recently published a report outlining the top 18 drug-
resistant threats. Three were classiﬁed as “urgent” in terms of threat level:
carbapenem-resistant Enterobacteriaceae (CRE), Clostridium difﬁcile, and Neisseria
gonorrhoeae (1). Carbapenems are broad-spectrum -lactam antibiotics saved for
the treatment of the most serious infections. CRE have become resistant to all or
nearly all antibiotics available and cause many types of serious infections, such as
infections of the respiratory tract, urinary tract and abdomen and bacteremia (2).
The CDC estimates that 9,300 health care-associated infections are caused each year
in the United States by the two most common types of CRE, carbapenem-resistant
Klebsiella species and Escherichia coli species, which are responsible for approxi-
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mately 600 deaths (1). In China, among the 664 CRE cases reported in 2015 in 25
hospitals, most were caused by Klebsiella pneumoniae (73.3%), E. coli (16.6%), or
Enterobacter cloacae (7.1%), and the overall mortality rate was 33.5% (2).
Antibacterial activity screening of a collection of Xenorhabdus strains led to the
discovery of the odilorhabdins (ODLs), a new antibiotic class with broad-spectrum
activity against Gram-positive and Gram-negative pathogens (3). Odilorhabdins inhibit
bacterial translation by a new mechanism of action on ribosomes (3). Their chemical
tractability made them suitable for a lead optimization program by medicinal chemistry
that led to the preclinical candidate NOSO-502 (Fig. 1).
We report here the in vitro and in vivo characterization of NOSO-502. The data
demonstrate that NOSO-502 is active against a panel of Gram-positive and Gram-
negative bacteria, including carbapenem-resistant and polymyxin-resistant strains, and
exhibits promising in vivo activity in various murine infection models, a favorable in
vitro safety proﬁle, and a low potential for resistance development.
RESULTS
NOSO-502 exhibits potent antibacterial activity. The antibacterial activity spec-
trum of NOSO-502 was assessed by testing a panel of Gram-positive and Gram-negative
wild-type strains. The compound was active against Gram-negative pathogens of the
Enterobacteriaceae family, such as E. coli or K. pneumoniae, with MIC values between 0.5
and 4 g/ml, as well as Stenotrophomonas maltophilia. In comparison, the MIC values
of NOSO-502 against Pseudomonas aeruginosa and Acinetobacter baumannii were 64
g/ml. For Gram-positive species, NOSO-502 was more active against staphylococci
than Enterococcus or Streptococcus strains (Table 1).
FIG 1 Chemical structure of NOSO-502.
TABLE 1 Bacterial susceptibility proﬁle of NOSO-502 against reference bacterial strainsa
Strain
MIC (g/ml) of antibiotic
NOS CIP GEN IPM TGC PMB
Citrobacter freundii DSM 30039 2 0.125 0.5 1 1 0.5
Citrobacter kozeri DSM 4595 2 0.125 0.25 4 1 0.25
Enterobacter aerogenes DSM 30053 2 0.125 0.25 2 1 0.5
Enterobacter cloacae DSM 14563 2 0.125 0.5 1 4 1
Escherichia coli ATCC 25922 4 0.125 1 0.25 0.25 0.5
Klebsiella pneumoniae ATCC 43816 1 0.125 0.25 1 2 1
Serratia marcescens DSM 17174 4 0.125 0.5 2 4 32
Acinetobacter baumannii ATCC 19606 64 2 16 0.5 1 0.5
Pseudomonas aeruginosa DSM 1117 64 1 1 2 8 1
Stenotrophomonas maltophilia ATCC 13637 16 1 4 64 0.5 1
Enterococcus faecalis DSM 2570 64 2 16 1 0.25 32
Enterococcus faecium DSM 20477 64 16 8 4 0.125 32
Staphylococcus aureus ATCC 29213 1 0.25 0.5 0.125 0.5 16
Staphylococcus epidermidis ATCC 12228 0.25 0.25 0.125 0.125 0.5 16
Streptococcus pneumoniae DSM 2134 64 1 8 0.125 0.125 32
aNOS, NOSO-502; CIP, ciproﬂoxacin; GEN, gentamicin; PMB, polymyxin B; IPM, imipenem; TGC, tigecycline.
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The compound was also tested against a recent panel of Enterobacteriaceae clinical
isolates. MIC90 values were between 2 and 8 g/ml against E. coli, K. pneumoniae,
Enterobacter cloacae, and Citrobacter freundii. The MIC range of NOSO-502 was narrow
against C. freundii and E. cloacae (1 to 4 g/ml) but wider against E. coli (1 to 32 g/ml)
and K. pneumoniae (0.5 to 16 g/ml). Nevertheless, only 3 isolates of E. coli and K.
pneumoniae out of 101 and 57 tested, respectively, exhibited MIC values slightly higher
than the MIC90 (E. coli, 2 isolates at 16 g/ml and 1 at 32 g/ml; K. pneumoniae, 1 isolate
at 4 g/ml, 1 at 8 g/ml, and 1 at 16 g/ml). The antibacterial activity of NOSO-502 was
conserved against ﬂuoroquinolone-, aminoglycoside-, and polymyxin B-resistant strains
in the panel (Table 2).
MIC values of NOSO-502 were determined against selected CRE and colistin-resistant
isolates. The CRE strains tested produce KPC enzymes (Ambler class A carbapenemase-
producing strains), metallo--lactamases, such as NDM, VIM, or IMP (Ambler class B
carbapenemase-producing strains), AmpC (Ambler class C carbapenem-resistant strains),
TABLE 2MICs of NOSO-502 and comparators against a panel of recent clinical bacterial
strainsa
Organism (no. of isolates) Antibiotic
MIC (g/ml)
Range 50% 90%
Citrobacter freundii (16) NOS 1–4 2 2
CIP 0.008–1 0.03 1
GEN 0.5–32 1 32
PMB 0.25–1 0.5 1
Enterobacter cloacae (13) NOS 1–4 1 2
CIP 0.016–1 1 1
GEN 1–32 32 32
PMB 0.5–16 0.5 8
Escherichia coli (101) NOS 2–32 4 8
CIP 0.008–1 0.03 1
GEN 0.5–32 1 2
PMB 0.25–32 0.5 1
Ciproﬂoxacin-resistant E. coli (19) NOS 2–32 4 8
CIP 1 1 1
GEN 0.13–32 0.5 32
PMB 0.5–32 0.5 1
Gentamicin-resistant E. coli (6) NOS 4
CIP 0.25–1
GEN 32–32
PMB 0.25–32
Polymyxin B-resistant E. coli (2) NOS 4–8
CIP 1–1
GEN 1–32
PMB 4–32
Klebsiella pneumoniae (56) NOS 0.5–16 1 2
CIP 0.008–1 0.5 1
GEN 0.5–32 1 32
PMB 0.25–32 0.5 4
Ciproﬂoxacin-resistant K. pneumoniae (27) NOS 0.5–16 1 2
CIP 1 1 1
GEN 0.13–32 32 32
PMB 0.5–32 0.5 1
Gentamicin-resistant K. pneumoniae (16) NOS 0.5–2 1 2
CIP 0.5–1 1 1
GEN 32–32 32 32
PMB 0.5–1 0.5 1
aMIC50 and MIC90 were calculated for populations with 10 isolates.
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and OXA-48 enzymes (Ambler class D carbapenemase-producing strains). NOSO-502 ex-
hibited potent activity against all carbapenemase-producing Enterobacteriaceae strains
(Table 3) and overcame multiple mechanisms of colistin acquired resistance (chromosome-
encoded mutations or deletions of pmrA, pmrB, mgrB, or phoQ or expression of mcr-1,
mcr-2, ormcr-3), except mechanisms involvingmutations of the crrB gene (Table 4). The crrB
gene belongs to a two-component system named crrAB. Mutations in this gene are
responsible for the acquisition of colistin resistance via a lipopolysaccharide (LPS) modiﬁ-
cation and an upregulation of an RND-type efﬂux pump (4). The crrAB locus is variably
present in K. pneumoniae genomes and absent in E. coli (5).
NOSO-502 had rapid bactericidal activity against E. coli ATCC 25922 and K. pneu-
moniae ATCC 43816, causing a 3-log decrease in CFU per milliliter at 1 h (4 and 8
MIC) (Fig. 2). We observed regrowth of E. coli at 4 MIC. Such regrowth at 24 h is not
uncommon and has previously been reported for bactericidal antimicrobials, such as
ciproﬂoxacin against E. coli (6).
The propensity of bacteria to develop resistance to NOSO-502 was assessed by
determining the spontaneous frequency of resistance (FoR) to the compound with E.
coli ATCC 25922 and K. pneumoniae ATCC 43816. Mutants of E. coli resistant to 4 MIC
(16 g/ml) or 8 MIC (32 g/ml) of NOSO-502 were isolated at frequencies of 3.0 
109 and 5.0  1010, respectively. The frequencies of resistance of K. pneumoniae
were 2.4  109 at 4 MIC (4 g/ml) and 7  1010 at 8 MIC (8 g/ml).
NOSO-502 has a good in vitro safety proﬁle. The potential nephrotoxicity of
NOSO-502 was assessed in cells derived directly from human kidney tissue, human
renal proximal tubular epithelial cells (HRPTEpiC) and HK-2 cells. A multiplexed assay
with HRPTEpiC was used to assess cellular stress induced in vitro by NOSO-502. Three
parameters were measured: a decrease in cell viability, the expression of heat shock
protein 27 (HSP27), and the level of kidney injury molecule 1 (KIM-1). A decrease in cell
TABLE 3 Activities of NOSO-502 and comparators against carbapenem-resistant Enterobacteriaceae strains
Type of enzyme or organism and strain -Lactamase content
MIC (g/ml) of antibiotic
NOS CIP GEN IPM TGC PMB
Ambler class A carbapenemase
Escherichia coli PSP KPC-2  TEM-1  OXA-1 2 16 64 8 0.5 0.5
Escherichia coli COL KPC-2  TEM-1  CTX-M9 2 64 64 8 0.5 0.5
Escherichia coli MIN KPC-3  OXA-9 4 0.25 0.5 8 0.25 0.5
Klebsiella pneumoniae ATCC BAA-1905 KPC-2 1 64 32 64 4 0.5
Klebsiella pneumoniae A33504 KPC-2 SHV-11  TEM-1  CTX-M-2  OXA-9 1 32 64 16 2 0.5
Klebsiella pneumoniae ATCC BAA-1904 KPC-3 2 0.25 16 32 2 0.5
Enterobacter cloacae KBM15 KPC-2  TEM-1  OXA-9 1 32 8 32 8 0.5
Ambler class B carbapenemase
Escherichia coli BAA-2469 NDM-1 2 16 64 32 1 0.25
Escherichia coli BAA-2471 NDM-1 4 64 64 64 1 0.25
Escherichia coli MON NDM-5  CTX-M15  TEM-1 4 64 0.5 32 0.5 0.5
Escherichia coli GAL NDM-6  OXA-1  CTX-M15 2 64 2 32 0.5 0.25
Escherichia coli EGB957 VIM-1  OXA-48  TEM-1  CMY-4  OXA-1 4 64 64 64 1 0.5
Klebsiella pneumoniae ATCC BAA-2146 NDM-1  CTX-M15  TEM-1  CMY-6  OXA-1  SHV-1 0.5 64 64 64 32 1
Klebsiella pneumoniae NCTC 13443 NDM-1 1 64 64 64 4 0.5
Klebsiella pneumoniae LAM NDM-4  SHV-11  CTX-M15 1 64 64 32 2 0.5
Klebsiella pneumoniae NCTC 13439 VIM-1 1 16 1 32 2 0.5
Enterobacter cloacae 3047 NDM-1  CTX-M15  TEM-1  OXA-1 1 2 32 16 4 0.5
Ambler class C carbapenem resistant
Enterobacter cloacae 10.72 AmpC overexpressed  TEM-1  OXA-1 1 64 64 4 8 0.5
Citrobacter freundii MAU AmpC overexpressed  TEM-3 1 64 2 4 8 0.5
Ambler class D carbapenemase
Escherichia coli DOV OXA-48  TEM-1  CTX-M15  OXA-1 2 64 32 4 2 0.5
Klebsiella pneumoniae NCTC 13442 OXA-48 1 4 0.25 16 2 0.5
Klebsiella pneumoniae DUB OXA-48  CTX-M15  TEM-1  SHV-1  OXA-1  CMY-2 0.5 64 64 16 4 0.5
Enterobacter cloacae YAM OXA-48  CTX-M15  TEM-1  OXA-1  DHA-1 2 64 64 4 4 1
Enterobacter cloacae BEU OXA-48  CTX-M15  SHV-12  TEM-1  OXA-1  DHA-1 1 32 64 16 16 16
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viability is a very sensitive marker to detect general toxicity but is not sufﬁcient to
predict nephrotoxicity, whereas increases in the level of biomarkers, such as KIM-1 or
HSP27, are well correlated with dose levels of known nephrotoxic compounds (7, 8).
HSP27 is expressed in response to cellular stress to block the apoptotic pathway. KIM-1
is a well-accepted marker of renal proximal tubule injury. NOSO-502 showed no
cytotoxicity to HRPTEpiC and the molecule did not signiﬁcantly increase (5-fold) KIM-1
or HSP27 levels at concentrations up to 100 M (0.1-fold and 1.5-fold increases at 100
M in KIM-1 and HSP27 signals, respectively). Polymyxin B and gentamicin, used as
comparators in this study, showed different toxicity proﬁles. Polymyxin B was cytotoxic
at low concentrations (50% inhibitory concentration [IC50]  11.8 M) and induced a
TABLE 4 Bacterial susceptibility proﬁle of NOSO-502 against colistin-resistant strains
Type of strain and gene mutation or gene conferring
resistance (no. of isolates)
MIC range (g/ml)
NOS CSTa
Escherichia coli, colistin-resistant (25)
mcr-1 (21) 1–4 4–16
mcr-2 (1) 1 8
mcr-3 (1) 1 16
Unknown (2) 1–2 16
Klebsiella pneumoniae, colistin resistant (46)
pmrA G53S substitution (2) 1–2 32–128
pmrB T157P substitution (6) 0.25–16 8–32
pmrB L17Q substitution (1) 1 32
phoQ R16C substitution (1) 2 128
mgrB full deletion (5) 0.5–1 16–128
mgrB premature termination (6) 0.5–1 32–128
mgrB IS5 between 74 and 75 (4) 0.5–2 16–128
mgrB W20R substitution (1) 0.5 32
mgrB W47R substitution (1) 1 8
mgrB IS1R into promoter between 45 and 46 (3) 0.5–1 32–128
mgrB M27K substitution (1) 2 32
mgrB N42Y and K43I substitutions (1) 2 32
mgrB ISKpn14 into promoter between 28 and 29 (2) 0.5–2 64
mgrB IS903B between 69 and 70 (2) 0.25–1 64
mgrB IS1R between 44 and 45 (2) 1 128
mgrB ISKpn26-like between 74 and 75 (2) 1 128–128
crrB P151L substitution (1) 128 128
crrB G183V substitution (1) 64 128
crrB F84S substitution (1) 8 128
crrB N141Y substitution (1) 16 128
mcr-1 (1) 0.5 32
Unknown (1) 0.5 32
aCST, colistin.
FIG 2 Bactericidal activity of NOSO-502 at 4 and 8 MIC against E. coli ATCC 25922 and K. pneumoniae
ATCC 43816. Closed circles, drug-free control; closed squares, NOSO-502 at 4 MIC; closed triangles,
NOSO-502 at 8 MIC. Experiments were performed in triplicate. Each symbol represents the mean, and
error bars indicate the SEMs.
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signiﬁcant increase of KIM-1 and HSP27 levels at 12.1 and 9.7 M, respectively.
Gentamicin was not cytotoxic and did not increase KIM-1 levels at concentrations up to
100 M but induced a 5-fold increase of HSP27 levels at 22.4 M. NOSO-502 did not
show any effect on HK-2 cell viability at concentrations up to 512 M (0% inhibition
from 16 to 256 M and 9.4% inhibition at 512 M).
The cardiotoxic effect of NOSO-502 was evaluated using the automated patch clamp
human ether-a-go-go related gene (hERG) potassium channel assay. This test is now
accepted as an early predictor of potential cardiotoxicity and is used routinely at an
early stage in the drug discovery process. NOSO-502 did not signiﬁcantly inhibit hERG
currents at concentrations up to 512 M (2.6% inhibition at 256 M and 1.9% inhibition
at 512 M). We also measured the effect of the compound on the voltage-gated cardiac
sodium ion channel Nav 1.5. This channel is a key component for the initiation and
transmission of the electrical signal throughout the heart. The IC50 of NOSO-502 in the
patch clamp Nav 1.5 sodium channel assay was higher than 512 M.
The genotoxic potential of NOSO-502 was investigated using the micronucleus (MN)
assay. This test detects both aneugenic (whole chromosome) and clastogenic (chro-
mosome breakage) damage in interphase cells (9). There was no signiﬁcant increase of
micronuclei in cells treated with 512 M NOSO-502 versus an S9 medium negative
control (0.61% cells with micronuclei for NOSO-502 versus 0.7% for S9 medium).
NOSO-502 had no cytotoxic effect against mammalian HepG2 (human hepatocel-
lular carcinoma) cells at concentrations up to 512 M (0% inhibition from 16 to 256 M
and 4.2% inhibition at 512 M) and did not show any hemolytic activity at 100 M. The
compound (10 M) had no signiﬁcant activity against any of the 55 cell surface
receptors or enzymes tested in a broad-based screen.
NOSO-502 is resistant to biotransformation by hepatocytes and microsomes.
NOSO-502 was resistant to biotransformation when incubated in mouse, rat, dog,
monkey, and human liver microsomes and hepatocytes during the in vitro study
conducted to evaluate metabolic stability. After 45 min, 70.5 to 78.6% of NOSO-502
remained after incubation with microsomes of the different species. The half-lives of
NOSO-502 were 116, 129, 101, 147, and 145 min in mouse, rat, dog, monkey, and
human liver microsomes, respectively. After 60 min, 79.5 to 91.9% of NOSO-502
remained after incubation with hepatocytes of the different species. The half-lives of
NOSO-502 in hepatocytes were 192, 194, 483, 698, and 329 min for mouse, rat, dog,
monkey, and human microsomes, respectively.
NOSO-502 shows variable stability in plasma of different species. NOSO-502
showed variable stability to biotransformation when incubated in mouse, rat, dog,
monkey, and human plasma; 10.1 to 61.2% of NOSO-502 remained after incubation
with plasma of the different species over the 120-min test period. The half-lives of
NOSO-502 were 54, 36, 158, 96, and 79 min in mouse, rat, dog, monkey, and human
plasma, respectively.
Pharmacokinetics. The pharmacokinetics of NOSO-502 were evaluated in normal
female CD-1 mice or normal female Sprague-Dawley rats. NOSO-502 was administered
intravenously at 30 mg/kg of body weight to mice and 15 mg/kg to rats. The
concentration-versus-time curves and the results of the pharmacokinetic analysis are
summarized in Fig. 3. In mice, NOSO-502 displayed moderate clearance (1.13 liters/h/
kg), a moderate volume of distribution (0.66 liters/kg), and a half-life of 25 min. The
pharmacokinetics of NOSO-502 in rats showed a longer half-life (90 min) but were
consistent with the results in mice, with a plasma clearance of 1.92 liters/h/kg and a
volume of distribution of 0.94 liter/kg. NOSO-502 showed moderate plasma protein
binding, with 19.8, 20.5, 17.6, and 18.7% unbound in mouse, rat, dog, and human
plasma, respectively.
NOSO-502 shows efﬁcacy in several murine infection models. The efﬁcacy of
NOSO-502 was evaluated in murine infection models to determine whether NOSO-502
has potential as a clinical therapy. In vivo efﬁcacy studies were conducted by admin-
istering NOSO-502 subcutaneously (s.c.). The efﬁcacy of NOSO-502 was ﬁrst assessed in
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a neutropenic murine sepsis infection model. This model, with E. coli EN122 (extended-
spectrum -lactamase [ESBL], clinical isolate; MIC of NOSO-502  4 g/ml), was
established in female NMRI mice. NOSO-502 was administered subcutaneously 1 h
postinoculation at set concentrations of 1.3, 2.5, 5, 10, 20, and 40 mg/kg, whereas
colistin was administered by the same route at 5 mg/kg. Five hours postchallenge,
blood samples were collected, and the mice were euthanized. Blood was serially plated
and colonies enumerated to determine the CFU per milliliter of blood. NOSO-502 was
highly effective, achieving a 50% effective dose (ED50) of 3.5 mg/kg and 1-, 2-, and 3-log
reductions in blood burden at 2.6, 3.8, and 5.9 mg/kg, respectively (Fig. 4).
A mouse E. coli UTI89 (MIC of NOSO-502  4 g/ml) upper urinary tract infection
model was established in female C3H/HeN mice. Administration of 24 mg/kg of
NOSO-502 once daily resulted in a statistically signiﬁcant reduction in urine, bladder,
and kidney burdens relative to vehicle control animals. At 4 days postinfection, NOSO-
502 reduced the urine burden by 2.39 log10 CFU/ml (P  0.0001), the bladder burden
by 1.96 log10 CFU/ml (P  0.0012), and the kidney burden by 1.36 log10 CFU/ml (P 
0.0123) relative to vehicle (Fig. 5).
A neutropenic mouse E. coli ATCC BAA-2469 (NDM-1; MIC of NOSO-502  2 g/ml)
intraperitoneal (i.p.) sepsis infection model was established in male CD-1/ICR mice.
Ninety percent of the vehicle-treated mice succumbed to infection prior to the end of
the study. All NOSO-502-treated mice (4, 12, and 24 mg/kg) survived up to the end of
FIG 3 Pharmacokinetic studies with CD-1 mice (closed squares) and Sprague-Dawley rats (closed circles)
following intravenous dosing at 30 and 15 mg/kg, respectively. Each symbol represents the mean, and
error bars indicate the SEMs.
FIG 4 Efﬁcacy of NOSO-502 and colistin in a neutropenic murine sepsis infection model against E. coli
EN122. Each symbol represents an individual mouse, and the horizontal line indicates the mean. Error
bars indicate the SEMs. Statistically signiﬁcant reduction versus vehicle control (one-way analysis of
variance [ANOVA], Dunnett’s comparison) is indicated as follows: ns, not signiﬁcant; *, P  0.05; **, P 
0.01; ***, P  0.001; ****, P  0.0001.
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the study at 24 h (P  0.0009 relative to vehicle). The vehicle group had mean and
median survival times of 19.8 h and 20.2 h, respectively. One subcutaneous adminis-
tration of NOSO-502 resulted in statistically signiﬁcant dose-dependent reductions in
blood and i.p. wash burdens relative to vehicle control animals at all doses. Treatment
with 4 mg/kg of NOSO-502 reduced the blood and i.p. wash burdens by 1.48 log10
CFU/ml (P  0.0081) and 0.68 log10 CFU/ml (P  0.0145), respectively. Treatment with
12 mg/kg reduced the blood burden by 2.14 log10 CFU/ml (P  0.0001) and the i.p.
wash burden by 2.07 log10 CFU/ml (P 0.0001), and treatment with 24 mg/kg reduced
the blood burden by 2.37 log10 CFU/ml (P  0.0001) and the i.p. wash burden by 2.74
log10 CFU/ml (P  0.0001) (Fig. 6).
A neutropenic mouse K. pneumoniae NCTC 13442 (OXA-48; MIC of NOSO-502  1
g/ml) lung infection model was established in male CD-1/ICR mice. NOSO-502 was
administered subcutaneously 2 h, 8 h, 14 h, and 20 h postinoculation at set concen-
trations of 2, 6, and 20 mg/kg (equivalent to 8, 24, and 80 mg/kg/day), whereas
tigecycline was administered by the same route at 40 mg/kg (equivalent to 160
mg/kg/day). NOSO-502 was also administered once 2 h postinoculation at 80 mg/kg.
Twenty-six hours postchallenge, mice were euthanized, and the lungs were collected.
Administration of NOSO-502 resulted in statistically signiﬁcant reductions in lung
burdens relative to vehicle control animals at all doses. Treatment with 8, 24, and 80
mg/kg/day of NOSO-502 reduced the lung burden by 2.69, 3.99, and 4.07 log10
CFU/gram of lung tissue, respectively (P  0.0001). Treatment with 80 mg/kg once
reduced the lung burden by 3.98 log10 CFU/gram of lung tissue (P  0.0001), and
treatment with 160 mg/kg/day of tigecycline reduced the lung burden by 3.14 log10
CFU/gram of lung tissue (P  0.0001) (Fig. 7).
DISCUSSION
The urgent need to discover new antibiotics active against Gram-negative bacteria
with a novel mechanism of action to counter the threat of drug-resistant infection is
widely recognized. NOSO-502 is the ﬁrst preclinical candidate of a novel antibiotic class,
the odilorhabdins (ODLs). ODLs are cationic peptides that inhibit bacterial translation
by a novel mechanism of action. ODLs bind to the small subunit of bacterial ribosomes
at a site not exploited by any known ribosome-targeting antibiotic. When bound to the
ribosome, ODLs make contacts with both the rRNA and tRNA and kill bacteria by
interfering with the decoding of genetic information and inhibiting ribosome progres-
sion along the mRNA in a context-speciﬁc manner (3).
NOSO-502 is active against Enterobacteriaceae, including CRE belonging to all
classes of the Ambler classiﬁcation and resistant to gentamicin, polymyxin B, or
FIG 5 Efﬁcacy of NOSO-502 and ciproﬂoxacin in a murine UTI model against E. coli UTI89. Each symbol represents an individual mouse, and the horizontal line
indicates the mean. Error bars indicate the SEMs. Statistically signiﬁcant reduction versus vehicle control (Kruskal-Wallis statistical test, multiple comparison) is
indicated as follows: ns, not signiﬁcant; *, P  0.05; **, P  0.01; ***, P  0.001; ****, P  0.0001.
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tigecycline. This is crucial, because these antibiotics, classically used for the treatment
of such infections, are associated with high levels of resistance, ranging from 9.7 to
51.3% (mean, 22.6%) for colistin, 5.6 to 85.4% (mean, 43.5%) for gentamicin, and 0 to
33% (mean, 15.2%) for tigecycline (10, 11, 12, 13, 14, 15, 16, 17, 18, 19). Current options
FIG 6 Efﬁcacy of NOSO-502 and tigecycline in a survival neutropenic sepsis infection model against E. coli
ATCC BAA-2469 (NDM-1). Each symbol represents an individual mouse, and the horizontal line indicates
the mean. Error bars indicate the SEMs. Statistically signiﬁcant reduction versus vehicle control (Kruskal-
Wallis statistical test, multiple comparison) is indicated as follows: ns, not signiﬁcant; *, P  0.05; **, P 
0.01; ***, P  0.001; ****, P  0.0001.
FIG 7 Efﬁcacy of NOSO-502 and tigecycline in a murine lung infection model against K. pneumoniae
NCTC 13442 (OXA-48). Each symbol represents an individual mouse, and the horizontal line indicates the
mean. Error bars indicate the SEMs. Statistically signiﬁcant reduction versus vehicle control (one-way
ANOVA, Dunnett’s comparison) is indicated as follows: ns, not signiﬁcant; *, P  0.05; **, P  0.01; ***,
P  0.001; ****, P  0.0001.
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to address these resistance issues are not entirely satisfactory, because none of the
recently approved antibiotics or those under development are effective against all CRE.
The combination ceftazidime-avibactam displays in vitro activity against CRE isolates
that produce KPC, AmpC, and OXA enzymes. However, this drug is not active against
metallo--lactamases, such as NDM, IMP, or VIM (20). This combination was approved
by the U.S. Food and Drug Administration (FDA) in 2015 and by the European
Medicines Agency in 2016 for treating complicated urinary tract (cUTI) and intra-
abdominal infections. Another drug approved by the FDA in 2017 for treatment of adult
patients with cUTI (including acute pyelonephritis) is the combination meropenem-
vaborbactam. But this drug is active only against KPC-producing strains within the CRE
group (21). Except eravacycline (a new tetracycline), none of the investigational anti-
microbials (plazomicin, a new aminoglycoside, or omadacycline, a new tetracycline) or
novel combinations, such as aztreonam and avibactam or imipenem and relebactam-
cilastatin, are effective against all classes of carbapenemases like NOSO-502 (22, 23).
Recently, CRE have caused numerous outbreaks of severe nosocomial infections and
have become endemic in several countries (24, 25, 26, 27, 28). These infections have
been associated with mortality rates exceeding 50% in some reports (29, 30, 31, 32).
NOSO-502 can overcome multiple mechanisms of colistin-resistant strains. Further-
more, the compound demonstrated rapid bactericidal activity and a low potential for
the development of resistance.
NOSO-502 is effective in mouse models of serious hospital-acquired infections. It
provided signiﬁcant protection against the Gram-negative pathogens E. coli and K.
pneumoniae, the highest-incidence pathogens in complicated intra-abdominal and
urinary tract infections, in septicemia following peritoneal challenge, and in acute
pyelonephritis. NOSO-502 was active in mouse infection models against E. coli strains
expressing the metallo--lactamase NDM-1 and resistant to other major antibiotic
classes, including ﬂuoroquinolones, macrolides, aminoglycosides, -lactams, cephalo-
sporins, and carbapenems. These results are encouraging and show the strong poten-
tial for in vivo efﬁcacy of NOSO-502. Effective doses will be optimized after the best
dosing schedule is deﬁned during a pharmacokinetic-pharmacodynamic (PKPD) study.
NOSO-502 showed a good safety proﬁle, with no in vitro nephrotoxicity, cardiotox-
icity, genotoxicity, or cytotoxicity at concentrations up to 512 M. Nephrotoxicity is a
serious side effect of many drugs, including cationic antibiotics aminoglycosides and
polymyxins (33, 34, 35). Polymyxins accumulate extensively within proximal tubular
cells (PTCs) of the kidneys, where they induce damage, which may lead to acute kidney
injury (AKI) in patients (36). AKI is the major dose-limiting adverse effect of this class of
antibiotics and affects 50 to 60% of patients receiving them (35, 37). Aminoglycosides
are ﬁltered across the glomerulus and then excreted, with 5 to 10% of a parenteral dose
being taken up and sequestered by the PTCs, in which the aminoglycoside can achieve
high concentrations (38). AKI due to acute tubular necrosis is a relatively common
complication of aminoglycoside therapy and affects 10 to 20% of patients (33, 34). The
results of NOSO-502 on HRPTEpiC and HK-2 cells are promising but must be conﬁrmed
by histopathological examination of kidney cells following in vivo administration to
animals, the standard assay for studying nephrotoxicity effects.
Cardiotoxicity issues are associated with many antibiotics, including macrolides,
ketolides, and ﬂuoroquinolones. These classes have been associated with prolongation
of cardiac repolarization. All these agents produce a blockage of the hERG channel-
dependent potassium current in myocyte membranes, resulting in a prolonged QTc
interval, which may give rise to ventricular ﬁbrillation or tachycardia (39). Nav 1.5 is
another channel involved in cardiotoxicity issues. Its activation induces depolarization
of the cell membrane. Failure of the Nav 1.5 sodium channel to adequately conduct the
electrical current across the cell membrane can result in a potentially fatal disorder.
NOSO-502 did not show any effects on hERG or Nav 1.5 channels at high concentra-
tions.
In this study, we conﬁrmed that NOSO-502, like many other therapeutic peptides, is
safe and highly selective. NOSO-502 interacts strongly with a speciﬁc site on the 30S
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subunit of bacterial ribosomes but has no signiﬁcant activity against any of the 55 cell
surface receptors, transporters, or ion channels tested. There is increasing interest in
peptides in pharmaceutical research and development (R&D), and approximately 140
are currently being evaluated in clinical trials and more than 500 are in preclinical
development (40, 41). The main limitation of peptides is their predisposition to enzy-
matic degradation. Thus, most do not circulate in blood for more than a few minutes,
preventing their usefulness as therapeutic agents. However, NOSO-502 showed good
stability in plasma, microsomes, and hepatocytes, probably due to the presence in its
structure of three nonstandard amino acid residues: ,-diamino--hydroxybutyric acid
[Dab(OH)] at position 2 (N terminus), ,-dehydroarginine (Dha) at position 9 (C
terminus), and D-ornithine at position 5. This translates into relatively long half-lives in
mice and rats.
NOSO-502 represents a new class of very promising bacterial ribosomal inhibitors to
combat bacterial multidrug resistance.
MATERIALS AND METHODS
Bacterial strains and antimicrobial agents. Reference strains are from the German Collection of
Microorganisms and Cell Cultures (DSMZ), the American Type Culture Collection (ATCC), the National
Collection of Type Cultures (NCTC), and the Medical and Molecular Microbiology, Faculty of Science and
Medicine, University of Fribourg, Switzerland. Clinical strains used to determine the MIC90 of NOSO-502
came from hospitals in Warsaw, Poland, Copenhagen, Denmark, Cardiff, UK, and Madrid, Spain. NOSO-
502 was synthesized at Nosopharm, Nîmes, France. Ciproﬂoxacin (Sigma-Aldrich; no. 1134335), genta-
micin (Sigma-Aldrich; no. G1397), imipenem (Sigma-Aldrich; no. IO160), polymyxin B (Sigma-Aldrich; no.
92283), and tigecycline (Sigma-Aldrich; no. PZ0021) were provided by the manufacturer as standard
powders except for gentamicin and polymyxin B, in solution at 50 and 20 mg/ml, respectively.
MIC. MIC values were determined using Clinical and Laboratory Standards Institute (CLSI) broth
microdilution methodology, colony direct suspension, as described in CLSI document M07-A10 (42).
Time-dependent killing. Time-kill assays were performed by the broth macrodilution method,
according to the CLSI guideline M26-A (43).
Determination of mutation frequency. Bacterial strains were grown in antibiotic-free Luria-Bertani
broth at 35°C for 18 h. Approximately 109 CFU of each strain was plated in duplicate onto Mueller-Hinton
agar (MHA) plates containing NOSO-502 concentrations at 4 and 8 the MIC values. The plates were
read after 24 and 48 h of incubation at 35°C. The frequency of selected resistant mutants was calculated
as the ratio of the number of bacteria growing divided by the number of bacteria in the original
inoculum, which was calculated by plating several dilutions of the original inoculum.
Multiplexed HRPTEpiC cytotoxicity assay. The multiplexed cytotoxicity assay on human renal
proximal tubule epithelial cells (HRPTEpiC) was conducted by Euroﬁns Panlabs (Euroﬁns Panlabs, Inc., St.
Charles, MO) by using an image-based high content analysis (HCA) technique where cells were ﬁxed and
stained with nuclear dye to visualize nuclei and ﬂuorescently labeled antibodies to detect drug-induced
cellular injury and cellular stress arising from oxidative and chemical stress. Cells were seeded into
384-well plates and grown in RPMI 1640, 10% fetal bovine serum (FBS), 2 mM L-alanyl-L-glutamine, and
1 mM sodium pyruvate in a humidiﬁed atmosphere of 5% CO2 at 37°C. NOSO-502, gentamicin, and
polymyxin B were added 24 h after cell seeding. Compounds were serially diluted 3.16-fold and assayed
over 10 concentrations in a ﬁnal assay concentration of 0.5% dimethyl sulfoxide (DMSO) from 100 M
to 3.7 nM. At the same time, a time zero untreated cell plate was generated. After a 48-h incubation
period, cells were ﬁxed and stained with ﬂuorescently labeled antibodies and nuclear dyed to allow
visualization of nuclei, injured cells, and stressed cells. Injured cells were detected using a KIM-1 (kidney
injury molecule 1) antibody. Stressed cells were detected using an anti-HSP27 (heat shock protein 27)
antibody. Cell proliferation was measured by the signal intensity of the incorporated nuclear dye. The cell
proliferation assay output was referred to as the relative cell count. To determine the cell proliferation
endpoint, the cell proliferation data output was transformed to percentage of control (POC) using the
following formula: POC relative cell count in compound wells/relative cell count in vehicle wells 100.
The signal intensity of the incorporated cellular stress and injury measurements were normalized with
the relative cell count from each well. Automated ﬂuorescence microscopy was carried out using a
Molecular Devices ImageXpress micro-imager, and images were collected with a 4 objective.
Cytotoxicity testing. HK-2 and HepG2 cell cytotoxicity assays were run by Euroﬁns-Cerep (Cerep
cytotoxicity proﬁle; Euroﬁns-Cerep SA, Poitiers, France) as described in reference 44. Cell viability was
measured using a luciferase-coupled ATP-quantitation assay (CellTiter-Glo; Promega, Madison, WI). In this
assay, the luminescent signal is proportional to the amount of ATP and thus to the number of
metabolically competent cells; cell injury and death result in a marked decrease in intracellular ATP levels.
HK-2 and HepG2 cells were dispensed at 6,000 to 3,000 cells/5 l/well in white tissue-culture treated
96-well solid-bottom assay plates and incubated at 37°C for 16 h to allow cell attachment, followed by
the addition of NOSO-502 at 16, 32, 64, 128, 256, and 512 M. After compound addition, plates were
incubated for 48 h at 37°C. At the end of the incubation period, 5 l of CellTiter-Glo reagent was added,
the plates were incubated at room temperature for 30 min, and the luminescence intensity of each well
was determined. Each experiment was carried out in duplicate.
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hERG tail current inhibition. Inhibition of the human ether-a-go-go-related gene (hERG) cardiac
potassium ion channel was determined by Euroﬁns Panlabs (Euroﬁns Panlabs, Inc., St. Charles, MO) in
CHO-K1 (Chinese hamster ovary) cells stably transfected with human hERG cDNA using QPatch auto-
mated whole-cell patch clamp electrophysiology as described in reference 45. NOSO-502 was tested at
64, 256, and 512 M. In this method, the extracellular solution (control) is applied ﬁrst and the cell is
stabilized in the solution for 5 min. Then the test compound is applied from low to high concentrations
sequentially on the same cell, with 5 min for each test concentration, at room temperature.
Nav 1.5 peak current inhibition. Inhibition of the Nav 1.5 human sodium ion channel was
determined by Euroﬁns Panlabs in HEK-293 cells stably transfected with human Nav1.5 cDNA (type V
voltage-gated sodium channel alpha subunit, GenBank accession number NM_000335) using IonWorks
Quattro automated whole-cell patch clamp electrophysiology. NOSO-502 was tested at 4, 8, 16, 32, 64,
128, 256, and 512 M. In this method, the voltage protocol is applied prior to compound addition (Pre),
the compounds are added and incubated for 600 s at room temperature, and then the voltage protocol
is applied a ﬁnal time (Post) on the IonWorks Quattro.
In vitro micronucleus assay. The test was conducted by Euroﬁns Panlabs. CHO-K1 cells were
preloaded with a cell dye that stains the cytoplasm, after which the cells were treated with NOSO-502
at 32, 64, 128, 256, and 512 M for 24 h. At the end of the incubation period the cells were ﬁxed, and
their DNA was stained with Hoechst. The visualization and scoring of the cells was done using an
automated ﬂuorescence microscope coupled with proprietary automated image analysis software (46).
The percent micronucleated cells was calculated. A marginally positive result (“/”) is deﬁned as a
value signiﬁcantly higher than controls (t test, P  0.05) and at least 2-fold higher than controls. A
positive result (“”) is deﬁned as a value signiﬁcantly higher than controls (t test, P  0.05) and at least
3-fold higher than controls.
Hemolytic activity. Mouse red blood cells were washed with phosphate-buffered saline (PBS) and
resuspended in PBS to 10% (vol/vol). NOSO-502 was tested at a ﬁnal concentration of 100 M. PBS and
deionized water were used as 0 and 100% hemolytic controls, respectively. Assays were incubated at
35°C for 45 min. The release of hemoglobin in the supernatant was monitored by absorbance at 540 nm.
Experiments were performed in triplicate.
Hepatocyte stability. The hepatocyte metabolic stability assays were performed by Cyprotex
Discovery Ltd. (Macclesﬁeld, UK). This assay utilizes cryopreserved pooled hepatocytes from different
species (mouse, rat, dog, monkey, and human), stored in liquid nitrogen prior to use. Williams E media
supplemented with 2 mM L-glutamine, 25 mM HEPES, and NOSO-502 (NOSO-502 ﬁnal substrate
concentration of 1 M, test compound prepared in water; control compound ﬁnal substrate concentra-
tion of 3 M, ﬁnal DMSO concentration of 0.25%) were preincubated at 37°C prior to the addition of a
suspension of cryopreserved hepatocytes (ﬁnal cell density of 0.5  106 viable cells/ml in Williams E
media supplemented with 2 mM L-glutamine and 25 mM HEPES) to initiate the reaction. The ﬁnal
incubation volume was 500 l. Two control compounds were included with each species alongside an
appropriate vehicle control. The reactions were stopped by transferring an aliquot of the mixture to 40%
trichloroacetic acid (TCA) in water, containing an internal standard for the test compounds (NOSO-95216;
1 M ﬁnal concentration) or methanol for the control compounds, at various time points (0, 5, 10, 20, 40,
and 60 min). The termination plates were centrifuged at 2,500 rpm at 4°C for 30 min to precipitate the
protein. Following protein precipitation, the test compound sample supernatants were diluted with
analytical-grade water, whereas the control compounds were diluted with an internal standard (meto-
prolol) in water. The test compound samples were analyzed by liquid chromatography-tandem mass
spectrometry (LC-MS/MS).
Microsome stability. The microsome metabolic stability assays were performed by Cyprotex Dis-
covery Ltd. (Macclesﬁeld, UK). Pooled microsomes from different species (mouse, rat, dog, monkey, and
human) were stored at 80°C prior to use. Microsomes (ﬁnal protein concentration of 0.5 mg/ml), 0.1 M
phosphate buffer (pH 7.4), and NOSO-502 (test compound ﬁnal substrate concentration of 1 M, test
compound prepared in water; control compound ﬁnal substrate concentration of 3 M, ﬁnal DMSO
concentration of 0.25%) were preincubated at 37°C prior to the addition of NADPH (ﬁnal concentration
of 1 mM) to initiate the reaction. The ﬁnal incubation volume was 500 l. A minus cofactor control
incubation was included for each compound tested, in which 0.1 M phosphate buffer (pH 7.4) was added
instead of NADPH (minus NADPH). Two control compounds were included with each species. Each
compound was incubated for 0, 5, 15, 30, and 45 min. The control (minus NADPH) was incubated for 45
min only. The reactions were stopped by transferring an aliquot of the mixture to 40% TCA in water
containing an internal standard (NOSO-95216, 1 M ﬁnal concentration) for the test compounds, or
methanol for the control compounds, at the desired time points. The termination plates were centrifuged
at 2,500 rpm for 20 min at 4°C to precipitate the protein. Following protein precipitation, the test
compound sample supernatants were diluted with analytical-grade water, whereas the control com-
pounds were diluted with an internal standard (metoprolol) in water. The test compound samples were
analyzed by LC-MS/MS.
Plasma stability. The plasma stability assays were performed by Cyprotex Discovery Ltd. Species-
speciﬁc plasma (heparin anticoagulant) was adjusted to pH 7.4 at 37°C, and NOSO-502 or control
compound (test compound ﬁnal substrate concentration of 10 M, test compound prepared in water;
control compound ﬁnal substrate concentration of 1 M, ﬁnal DMSO concentration of 2.5%) was added
to initiate the reaction. The ﬁnal incubation volume was 200 l. All incubations were performed
singularly for each compound at each time point. A vehicle control incubation was included using either
water or DMSO, along with a control compound known to be metabolized speciﬁcally by each species.
Each compound was incubated for 0, 15, 30, 60, and 120 min at 37°C. The reactions were stopped by the
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addition of 40% TCA in water containing an internal standard (NOSO-95216, 1 M ﬁnal concentration)
for the test compounds, or methanol for the control compounds, at the appropriate time points. The
vehicle control incubation was incubated for 120 min only. The termination plates were centrifuged at
3,000 rpm for 45 min at 4°C to precipitate the protein. Following protein precipitation, the test
compound sample supernatants were diluted with analytical-grade water, whereas the control com-
pounds were diluted with an internal standard (metoprolol) in water. The test compound samples were
analyzed by LC-MS/MS.
Selectivity proﬁle. The afﬁnity of NOSO-502 tested at 10 Mwas assessed using radioligand binding
assays for 55 cell surface receptors, transporters, and ion channels by Euroﬁns-Cerep (Cerep diversity
proﬁle; Euroﬁns-Cerep SA, Poitiers, France). Receptors tested included those to adenosine (A1, A2A, and
A3), adrenergic agonists (alpha1, alpha2, beta1, and beta2), angiotensin II (AT1), bradykinin (B2), cannabi-
noid (CB1), chemokines (CCCR1 and CXCR2) cholecystokinin (CCK1), dopamine (D1 and D2S), endothelin
(ETa), -aminobutyric acid (GABA) nonselective, galanine, (GAL2), histamine (H1 and H2), melanocortin
(MC4), muscarinic agonists (M1, M2, and M3), neurokinin (NK2 and NK3), neuropeptide Y (Y1 and Y2),
neurotensin (NTS1), opioid and opioid-like substances (delta2, kappa, mu, NOP), prostanoid (EP4),
serotonin (5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT5A, 5-HT6, and 5-HT7), somatostatin (sst), vasoactive
intestinal peptide (VPAC1), and vasopressin (V1a). Transporters tested included the dopamine transporter
(DAT), norepinephrine transporter (NET), and serotonin transporter (5-HT). Ion channels tested included
those for potassium (Kv and SKca channels) calcium (Ca2 channel, L-type, verapamil site), sodium (Na
channel site 2), GABA (BZD and Cl channel GABA gated), and serotonin (5-HT3). Receptor, transporter,
or ion channel binding by a speciﬁc ligand was deﬁned as the difference between total and nonspeciﬁc
binding, determined in the presence of an excess of unlabeled ligand. Results are expressed as the
percent inhibition of control-speciﬁc binding or the percent variation of control values obtained in the
presence of NOSO-502.
Pharmacokinetic analysis. Pharmacokinetic analyses were performed by Pharmacelsus (Saar-
brücken, Germany). CD-1 female mice and female Sprague-Dawley rats were injected intravenously with
30 and 15 mg/kg of NOSO-502, respectively, prepared in saline (5 ml/kg). Blood (100 l) was collected
from three animals per time point (5, 10, 20, 30, 60, and 120 min postdose for mice and 5, 15, 30, 60, 180,
and 420 min postdose for rats) in tubes containing K3-EDTA as an anticoagulant. Samples were stored
on ice and centrifuged at 6,000 rpm for 10 min at 4°C. A sample volume of 50 l was mixed with 5 l
of solvent (acetonitrile-H2O-DMSO, [5/4/1, vol/vol/vol] plus 1% formic acid). A volume of 10 l of solvent
containing the internal standard and 50 l of precipitant (10% TCA) were added to 55 l of sample. The
mixture was vortexed and centrifuged at 6,000  g (room temperature) for 10 min. The protein-free
supernatant was analyzed by LC-MS using an Ultimate 3000RS ultrahigh-performance liquid chromato-
graph (U-HPLC) coupled with an Orbitrap Q Exactive mass spectrometer.
Analytes were separated on a Accurore phenyl-hexyl analytical column (2.1 by 50 mm, 2.6 m;
Thermo, Germany) using a linear gradient of mobile phase A (acetonitrile-0.2% heptaﬂuorobutyric
acid)-mobile phase B (water-0.2% heptaﬂuorobutyric acid), starting from 5% mobile phase A to 97% in
2.2 min, and a ﬂow rate of 0.6 l/min. Peaks were analyzed by mass spectrometry (ESI ionization in MRM
mode) using Xcalibur 4.0 software. The products analyzed, [M  2H]2 and [M  3H]3, were 539.8 and
360.2 Da, respectively. PK parameters were calculated using a noncompartmental analysis model and
Kinetica 5.0 software (Thermo Scientiﬁc, Waltham, MA). The mean plasma concentrations from all three
mice at each time point were used in the calculation.
Plasma protein binding. The plasma stability assays were performed by Cyprotex Discovery Ltd.
(Macclesﬁeld, UK). This study was conducted to determine the extent of binding of NOSO-502 to the
proteins in human, monkey, dog, rat, and mouse plasma. Solutions of NOSO-502 or control compound
(NOSO-502 ﬁnal substrate concentration of 2 M in water; control compound ﬁnal substrate concen-
tration of 2 M, ﬁnal DMSO concentration of 0.5%) were prepared in 100% species-speciﬁc plasma
(collected using EDTA as the anticoagulant). The experiment was performed using equilibrium dialysis
(RED device) with the two compartments separated by a semipermeable membrane. Buffer (pH 7.4) was
added to one side of the membrane and the plasma solution to the other. After equilibration (4 h),
samples were taken from both sides of the membrane. Calibration standards were prepared in plasma
and buffer. All incubations were performed in triplicate. A control compound was included in each
experiment. Incubation of the control compound samples was terminated with acetonitrile containing an
internal standard (metoprolol). Incubation of the test compound samples was terminated with 40% TCA
in water containing in internal standard (NOSO-95216; 1 M ﬁnal concentration). All samples were
centrifuged and further diluted with water prior to analysis. The solutions for each batch of control
compounds were combined into two groups (protein free and protein containing) and cassette analyzed
by LC-MS/MS using two sets of calibration standards for protein-free (seven points) and protein-
containing solutions (seven points).
Mouse neutropenic peritonitis/sepsis model. NOSO-502 was tested against E. coli EN122 (MIC 
4 g/ml, ESBL, clinical isolate 106-EC-09, Denmark) in a murine neutropenic peritonitis/sepsis model.
Female NMRI mice (Taconic Biosciences A/S, Lille Skensved, Denmark) were used. Mice had ad libitum
access to domestic quality drinking water and food (2016 16% protein rodent diet; Harlan, USA) and were
exposed to a 12-h light/dark cycle. All animal experiments were approved by the National Committee of
Animal Ethics, Denmark, and adhered to the standards of EU directive 2010/63/EU. Mice were allowed to
acclimatize for 4 days, and thereafter neutropenia was induced by intraperitoneal injections of cyclo-
phosphamide (Baxter A/S, Søborg, Denmark) 4 days (200 mg/kg) and 1 day (100 mg/kg) prior to
inoculation. Overnight E. coli colonies were suspended in saline to 107 CFU/ml, and mice were inoculated
intraperitoneally with 0.5 ml of the suspension. At 1 h postinoculation, mice were treated with 1.3, 2.5,
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4, 10, 20, or 40 mg/kg NOSO-502, a vehicle (PBS [pH 7.4]), or 5 mg/kg of colistin (Sigma-Aldrich; no. 4461)
subcutaneously as a single dose in 0.2 ml. Four hours after treatment, mice were anesthetized and blood
was collected by axillary cutdown. Blood samples were serially diluted and plated on blood agar plates
(SSI Diagnostica, Hillerød, Denmark), with subsequent counting of colonies after incubation overnight at
35°C in ambient air. The mice were observed during the study for clinical signs of infection, such as lack
of curiosity, social withdrawal, changes in body position and patterns of movement, distress, or pain.
Mouse UTI model. All animal studies were performed under UK Home Ofﬁce license P2BC7D240
with local ethical committee clearance. All studies were performed by technicians who completed parts
A, B, and C of the UK Home Ofﬁce personal license course and hold current personal licenses. All
experiments were performed in dedicated biohazard 2 facilities (this site holds a certiﬁcate of designa-
tion).
NOSO-502 was tested against E. coli UTI89 (MIC  4 g/ml) in a mouse UTI model by Evotec
(Manchester, UK). Female C3H/HeN mice, 18 to 22 g (Janvier Laboratories, UK), were allowed to
acclimatize for 7 days. Following acclimatization, drinking water was replaced with water containing 5%
glucose from 5 days preinfection. Previously prepared frozen stocks of E. coli UTI89 were diluted to 1 
1010 CFU/ml immediately prior to infection. Mice were infected by directly administering a 0.05-ml
inoculum (5  108 CFU/mouse) via the urethra into the bladder under parenteral anesthesia (90 mg/kg
of ketamine and 9 mg/kg of xylazine). Bladders were emptied prior to infection, and once infected,
infection catheters were left in the urinary tract for 10 min to reduce the risk of the organism ﬂowing
back out. Following catheter removal, mice were allowed to fully recover in warmed humidiﬁed cages.
Dose formulations of NOSO-502 were prepared in 25 mM PBS. Treatment with 4, 12, and 24 mg/kg of
NOSO-502 was initiated 24 h postinfection and was administered once daily (q24h) by subcutaneous
injection or intravenously (ciproﬂoxacin) for 3 days. Mice were euthanized 96 h postinfection (three doses
administered). Ciproﬂoxacin (Bayer; lot BXHEFTI), administered at 10 mg/kg/dose intravenously twice a
day (BID), was included as a comparator (six doses administered), and 25 mM PBS was used as a vehicle.
Urine was collected 24 h postinfection from all animals and used to assess the infection level of each
mouse prior to initiation of treatment; all mice were successfully infected. In addition, ﬁve mice were
euthanized by pentobarbitone overdose to provide a 24-h pretreatment control group. The clinical
condition and body weight of all remaining animals were assessed and urine samples were collected 96
h postinfection. Animals were then euthanized by pentobarbitone overdose and the kidneys and
bladders removed and weighed. Tissue samples were homogenized using a Precellys 24 dual-bead
beater in 2 ml of ice-cold sterile PBS. Homogenates and urine samples were quantitatively cultured onto
MacConkey’s agar plates and incubated at 37°C for 24 h before colonies were counted. The data from the
culture burdens were analyzed using appropriate nonparametric statistical models (Kruskal-Wallis using
Conover-Inman to make all pairwise comparisons between groups) with StatsDirect software v. 2.7.8 and
compared to pretreatment and vehicle controls.
Mouse neutropenic i.p. sepsis model. All animal studies were performed under UK Home Ofﬁce
license P2BC7D240 with local ethical committee clearance. All studies were performed by technicians
who completed parts A, B, and C of the UK Home Ofﬁce personal license course and hold current
personal licenses. All experiments were performed in dedicated biohazard 2 facilities (this site holds a
certiﬁcate of designation).
NOSO-502 was tested against E. coli ATCC BAA-2469 (MIC  2 g/ml) in an i.p. sepsis model by
Evotec (Manchester, UK). Male CD1/ICR mice, 25 to 30 g (Charles River, UK), were allowed to acclimatize
for 11 days. Mice were rendered neutropenic with two intraperitoneal injections of 150 mg/kg of
cyclophosphamide 4 days before infection and 100 mg/kg 1 day before infection. Previously prepared
frozen stocks of E. coli ATCC BAA-2469 were diluted immediately prior to infection to 6.8  107 CFU/ml.
Mice were infected by directly administering a 0.5-ml inoculum (3.4  107 CFU/mouse) via intraperito-
neal injection. Dose formulations of NOSO-502 were prepared in 25 mM PBS. Treatment was initiated 1
h postinfection, and NOSO-502 doses (4, 12, and 24 mg/kg) were administered once by subcutaneous
injection. Tigecycline (MIC  0.5 g/ml), administered at 40 mg/kg/dose subcutaneously BID, was
included as a comparator, and two doses were administered. Animals from the pretreatment groups
were euthanized 1 h postinfection, and all remaining mice were euthanized 25 h postinfection. The
clinical condition and body weight of all remaining animals were assessed 25 h postinfection or when
animals reached the ethical severity endpoint (whichever came ﬁrst). Mice were anesthetized using 2.5%
isoﬂurane–97.5% oxygen, followed by a pentobarbitone overdose. When mice were deeply unconscious,
blood was collected from all animals under terminal cardiac puncture into EDTA blood tubes. In addition,
an intraperitoneal wash with sterile PBS (2 ml i.p. injected and 1 ml removed for culture) was collected.
Five mice were also euthanized by pentobarbitone overdose to provide a 1-h pretreatment control
group. Blood and i.p. wash samples were quantitatively cultured onto cystine lactose electrolyte-deﬁcient
(CLED) agar plates and incubated at 37°C for 24 h before colonies were counted. The data from the
culture burdens were analyzed using appropriate nonparametric statistical models (Kruskal-Wallis using
Conover-Inman to make all pairwise comparisons between groups) with StatsDirect software v.2.7.8 and
compared to pretreatment and vehicle controls.
Mouse lung infection model. All animal experiments were performed under UK Home Ofﬁce license
40/3644, and with local ethical committee clearance (The University of Manchester AWERB). All experi-
ments were performed by technicians who had completed at least parts 1 to 3 of the Home Ofﬁce
personal license course and held current personal licenses.
NOSO-502 was tested against K. pneumoniae NCTC 13442 (expresses OXA-48 carbapenemase, MIC 
1 g/ml) in a neutropenic mouse pulmonary infection model by Evotec (Manchester, UK). Male CD-1/ICR
mice, 6 to 8 weeks old (Charles River UK), were allowed to acclimatize for 7 days and then rendered
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neutropenic by i.p. injection of cyclophosphamide (200 mg/kg on day 4 and 150 mg/kg on day 1 before
infection). Mice were infected by the intranasal route (4  106 CFU/mouse) under parenteral anes-
thesia. At 2 h, 8 h, 14 h, and 20 h postinfection, mice received treatments with NOSO-502 at 2, 6, or 20
mg/kg or with tigecycline at 40 mg/kg administered by the s.c. route in a volume of 10 ml/kg (8 mice
per dose). At 2 h postinfection, NOSO-502 was delivered once by the s.c. route at 80 mg/kg in a volume
of 10 ml/kg (8 mice). At 2 h postinfection, one infected group was humanely euthanized, and lungs were
processed for pretreatment quantitative culture to determine Klebsiella burdens. At 26 h postinfection,
all remaining mice were humanely euthanized. Lungs were aseptically removed, homogenized, serially
diluted, and plated on CLED agar for CFU titers.
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